Asher Biotherapeutics is developing a pipeline of cis-targeted immunotherapies that selectively activate only the immune cell types that drive the desired therapeutic response. The company was seeking a contract development and manufacturing organization (CDMO) that could handle Phase 2 through to commercial production of its lead candidates, as well taking early-stage projects in its pipeline all the way through their lifecycle. The technical capability and capacity of a large CDMO like Lonza was attractive, but Asher wanted to be sure that a large provider would be committed to its pipeline and offer flexibility in terms of technical approach and program structuring.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center